Drug Trial Radar · NCT03741179
Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy
Last checked: Nov 19, 2026Latest source record: Feb 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
974
Actual
Start
Aug 20, 2019
Primary completion
Jan 30, 2022
Study completion Jan 30, 2022
Sponsor
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pregnant women at a higher risk for pre-eclampsia (PE) should be offered preventive daily treatment with acetylsalicylic acid (ASA) started before 16 weeks of gestation. To select patients at higher risk for PE, multiparametric assessment combining maternal history, biochemical factors and biophysical factors should be used during the first trimester of pregnancy. Multiparametric risk assessments have a detection rate for early-onset PE around 80% at a false positive rate of 10%. Owing to the low prevalence of early-onset and preterm PE, more than 90% of patients considered at high risk, at the first-trimester screening, will not eventually develop PE. Thus, ASA treatment would be innecessary and could be safely discontinued in these patients. The sFlt-1 to PlGF ratio has a high negative predictive value for PE during the second and third trimester of pregnancy. Thus, it could be used to detect false-positive patients from the first-trimester screening. This is a multicentric, randomized, open, parallel, controlled, phase III trial, where 1,080 patients under treatment with ASA for being at high risk for preeclampsia from the first-trimester screening, will be candidates to participate. Patients with a sFlt-1/PlGF \<38, from 24 to 27+6 weeks of gestation will be randomized at a 1:1 ratio and allocated to either continue ASA until 36 weeks or to stop ASA treatment.
Conditions
- Pre-Eclampsia
Interventions
ASA-withdrawn groupDrug
Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of preterm pre-eclampsia in both arms of the study (ASA vs no ASA).Time frame: From 24+0 weeks of gestation onwards
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.